EP 2459535 B1 20150325 - PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS
Title (en)
PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS
Title (de)
PYRIDIN- UND PYRAZINDERIVATE ALS PROTEINKINASEMODULATOREN
Title (fr)
DÉRIVÉS DE LA PYRIDINE ET DE LA PYRAZINE EN TANT QUE MODULATEURS DE LA PROTÉINE KINASE
Publication
Application
Priority
- US 27315409 P 20090730
- US 35772010 P 20100623
- EP 2010060984 W 20100728
Abstract (en)
[origin: US2011028492A1] The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.
IPC 8 full level
C07D 213/74 (2006.01); A61K 31/506 (2006.01); A61P 29/00 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01)
CPC (source: EP KR US)
A61K 31/4545 (2013.01 - KR); A61K 31/497 (2013.01 - US); A61P 1/00 (2017.12 - EP); A61P 1/18 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 11/00 (2017.12 - EP); A61P 13/10 (2017.12 - EP); A61P 13/12 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 17/06 (2017.12 - EP); A61P 19/00 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 31/10 (2017.12 - EP); A61P 31/12 (2017.12 - EP); A61P 31/18 (2017.12 - EP); A61P 33/00 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 213/74 (2013.01 - EP KR US); C07D 401/04 (2013.01 - EP KR US); C07D 401/12 (2013.01 - EP US); C07D 401/14 (2013.01 - EP US); C07D 405/14 (2013.01 - EP US); C07D 409/14 (2013.01 - EP US); C07D 413/14 (2013.01 - EP US); C07D 241/20 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
Designated extension state (EPC)
BA ME RS
DOCDB simple family (publication)
US 2011028492 A1 20110203; US 8415381 B2 20130409; AR 077505 A1 20110831; AU 2010277588 A1 20120119; AU 2010277588 B2 20121220; BR 112012008074 A2 20160301; CA 2767066 A1 20110203; CL 2012000092 A1 20120803; CN 102482218 A 20120530; CN 102482218 B 20150121; CO 6612188 A2 20130201; CR 20120051 A 20120326; CU 20120015 A7 20120415; CU 24091 B1 20150429; DO P2012000025 A 20120615; EA 023561 B1 20160630; EA 201200209 A1 20120830; EC SP12011638 A 20120229; EP 2459535 A1 20120606; EP 2459535 B1 20150325; ES 2536479 T3 20150525; GE P20146101 B 20140527; GT 201200022 A 20131210; IL 217524 A0 20120229; IL 233040 A0 20140731; JP 2013500311 A 20130107; JP 2015052005 A 20150319; JP 5650735 B2 20150107; KR 101464052 B1 20141120; KR 20120038015 A 20120420; MA 33540 B1 20120801; MX 2012001281 A 20120316; MY 183373 A 20210218; NI 201200016 A 20120815; NZ 597551 A 20131025; PE 20121127 A1 20120816; SG 177660 A1 20120329; TW 201107307 A 20110301; US 2013172354 A1 20130704; US 2014288076 A1 20140925; US 8778951 B2 20140715; UY 32810 A 20110228; WO 2011012661 A1 20110203; ZA 201109166 B 20130527
DOCDB simple family (application)
US 84349410 A 20100726; AR P100102732 A 20100728; AU 2010277588 A 20100728; BR 112012008074 A 20100728; CA 2767066 A 20100728; CL 2012000092 A 20120112; CN 201080033688 A 20100728; CO 12023085 A 20120209; CR 20120051 A 20120130; CU 20120015 A 20120126; DO 2012000025 A 20120127; EA 201200209 A 20100728; EC SP12011638 A 20120130; EP 10736734 A 20100728; EP 2010060984 W 20100728; ES 10736734 T 20100728; GE AP2010012602 A 20100728; GT 201200022 A 20120127; IL 21752412 A 20120112; IL 23304014 A 20140609; JP 2012522168 A 20100728; JP 2014230877 A 20141113; KR 20127005200 A 20100728; MA 34654 A 20120227; MX 2012001281 A 20100728; MY PI2012000154 A 20100728; NI 201200016 A 20120127; NZ 59755110 A 20100728; PE 2012000119 A 20100728; SG 2012002770 A 20100728; TW 99125158 A 20100729; US 201313773052 A 20130221; US 201414295398 A 20140604; UY 32810 A 20100729; ZA 201109166 A 20111213